<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00237900</url>
  </required_header>
  <id_info>
    <org_study_id>1839IL/0539</org_study_id>
    <nct_id>NCT00237900</nct_id>
  </id_info>
  <brief_title>Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer</brief_title>
  <official_title>An Open, Single.Centre, Phase I/II Study of ZD1839 (Iressa) in Combination With 5-Fluorouracil, Leucovorin and Radiotherapy in Subjects With Resectable Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      To assess safety, efficacy and explorative objectives of gefitinib in combination with
      chemoradiation in resectable gastric cancer
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Safety and tolerability of gefitinib 250 mg in combination with radiotherapy (incidence of DLTs)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 2 and 3: Safety and tolerability of gefitinib in combination with 5-FU, LV and radiotherapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parts 2 and 3:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumour response rate a week before surgery (CR and PR, RECIST criteria).</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective histological response rate in dissected GC specimens taken at surgery, estimated using Evans/Pisters scores</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory outcome: Parts 2 and 3: sVEGF levels, EGFR activation, Biomarkers such as cyclin D1, IL-1, GI-associated TOP2A, GAS, EST AA552509</measure>
  </secondary_outcome>
  <enrollment>34</enrollment>
  <condition>Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib, 5-fluorouracil, leucovorin and radiotherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically-confirmed intestinal GC (T2-T4)

          -  Local or locally advanced stage II or stage III gastric cancer of an upper part of the
             stomach or GE junction

          -  Lymph node positive or negative

          -  Metastasis negative

          -  Resection with curative intent (R0, D2)

          -  Chemo- and radiotherapy na√Øve

          -  Measurable lesion according RECIST

          -  Written informed consent

        Exclusion Criteria:

          -  Aged below 45 or over 70

          -  Prior gastric surgery

          -  Active ILD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca Oncology Medical Science Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reseach Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2005</study_first_submitted>
  <study_first_submitted_qc>October 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2005</study_first_posted>
  <last_update_submitted>April 22, 2009</last_update_submitted>
  <last_update_submitted_qc>April 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

